Prothena Corporation plc (PRTA)
Largest Insider Buys in Sector
PRTA Stock Price History Chart
PRTA Stock Performance
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and …
Insider Activity of Prothena Corporation plc
Over the last 12 months, insiders at Prothena Corporation plc have bought $0 and sold $170,000 worth of Prothena Corporation plc stock.
On average, over the past 5 years, insiders at Prothena Corporation plc have bought $54.55M and sold $25.48M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,062,736 shares for transaction amount of $30.84M was made by EcoR1 Capital, LLC () on 2022‑05‑05.
List of Insider Buy and Sell Transactions, Prothena Corporation plc
| 2024-01-24 | Sale | Chief Accounting Officer | 5,000 0.0096% | $34.00 | $170,000 | -35.55% | ||
| 2023-12-20 | Sale | Chief Accounting Officer | 5,000 0.0094% | $37.19 | $185,952 | -41.59% | ||
| 2023-11-30 | Sale | Chief Accounting Officer | 5,000 0.0097% | $34.00 | $170,000 | -31.29% | ||
| 2023-10-25 | Sale | Chief Accounting Officer | 5,000 0.0097% | $41.04 | $205,191 | -39.39% | ||
| 2023-10-11 | Sale | Chief Operating Officer | 4,000 0.0074% | $46.75 | $186,985 | -46.85% | ||
| 2023-10-04 | Sale | Chief Regulatory Officer | 5,000 0.0093% | $46.62 | $233,084 | -43.55% | ||
| 2023-09-27 | Sale | Chief Legal Officer | 5,000 0.0093% | $47.38 | $236,885 | -44.72% | ||
| 2023-09-19 | Sale | Chief Accounting Officer | 5,000 0.0093% | $52.36 | $261,807 | -48.68% | ||
| 2023-09-13 | Sale | Chief Operating Officer | 4,000 0.0075% | $55.49 | $221,963 | -49.31% | ||
| 2023-09-13 | Sale | Chief Medical Officer | 2,000 0.0037% | $55.48 | $110,952 | -49.31% | ||
| 2023-09-06 | Sale | Chief Regulatory Officer | 5,000 0.0093% | $54.76 | $273,804 | -49.33% | ||
| 2023-08-30 | Sale | Chief Legal Officer | 5,000 0.0095% | $55.01 | $275,066 | -47.85% | ||
| 2023-08-18 | Sale | Chief Accounting Officer | 5,000 0.0096% | $57.18 | $285,923 | -48.19% | ||
| 2023-08-16 | Sale | Chief Operating Officer | 4,000 0.0075% | $58.71 | $234,844 | -49.60% | ||
| 2023-08-16 | Sale | Chief Medical Officer | 2,000 0.0038% | $58.74 | $117,480 | -49.60% | ||
| 2023-08-02 | Sale | Chief Scientific Officer | 4,000 0.0075% | $67.05 | $268,182 | -51.93% | ||
| 2023-08-02 | Sale | Chief Regulatory Officer | 5,000 0.0094% | $67.01 | $335,072 | -51.93% | ||
| 2023-07-26 | Sale | Chief Legal Officer | 5,000 0.0095% | $62.33 | $311,638 | -47.96% | ||
| 2023-07-19 | Sale | Chief Accounting Officer | 5,000 0.0099% | $69.19 | $345,943 | -50.39% | ||
| 2023-07-12 | Sale | Chief Operating Officer | 4,000 0.0076% | $67.51 | $270,026 | -50.52% |
Insider Historical Profitability
| EcoR1 Capital, LLC | 11584280 21.5286% | $15.22 | 9 | 1 | +87.11% | |
| Kinney Gene G. | President and CEO | 12793 0.0238% | $15.22 | 1 | 13 | +13.42% |
| Schenk Dale B. | President and CEO | 3333 0.0062% | $15.22 | 1 | 2 | +5.51% |
| Nguyen Tran | Chief Strategy Officer and CFO | 3200 0.0059% | $15.22 | 2 | 10 | +10.25% |
| Nickerson Tara | Chief Business Officer | 2000 0.0037% | $15.22 | 1 | 7 | +5.51% |
Institutional Investor Ownership
| Ecor1 Capital Llc | $286.94M | 21.54 | 11.58M | 0% | +$0 | 2.01 | |
| Fidelity Investments | $198.32M | 14.89 | 8.01M | -0.54% | -$1.07M | 0.01 | |
| T. Rowe Price | $104.08M | 7.81 | 4.2M | -0.84% | -$881,326.19 | 0.01 | |
| Wellington Management Company | $92.94M | 6.98 | 3.75M | +44.64% | +$28.68M | 0.02 | |
| BlackRock | $92.11M | 6.92 | 3.72M | -1.38% | -$1.28M | <0.01 |